Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life-threatening diseases. The company is headquartered in Hayward, California and currently employs 21 full-time employees. The company went IPO on 2010-03-02. The firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.
Follow-Up Questions
Who is the CEO of Anthera Pharmaceuticals Inc?
Mr. J. Craig Thompson is the President of Anthera Pharmaceuticals Inc, joining the firm since 2016.
What is the price performance of ANTH stock?
The current price of ANTH is $0.0001, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Anthera Pharmaceuticals Inc?
Anthera Pharmaceuticals Inc belongs to Biotechnology industry and the sector is Health Care
What is Anthera Pharmaceuticals Inc market cap?
Anthera Pharmaceuticals Inc's current market cap is $2618
